Pacira BioSciences, Inc.
PCRXDrugs in Pipeline
20
Phase 3 Programs
13
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
ZILRETTA Phase 3 Est. Readout
Primary completion for ZILRETTA trial (NCT06269705) in Glenohumeral Osteoarthritis
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How PCRX's past catalysts played out
TCA IR 40
Osteoarthritis of the Knee
FX006
Osteoarthritis of the Knee
EXPAREL 67 mg
Postoperative Pain
ZILRETTA
Glenohumeral Osteoarthritis
Exparel
Postoperative Pain Management
Bupivacaine liposome injectable suspension 266 mg
Bunionectomy
bupivacaine liposome injectable suspension
Pain
Bupivacaine Hydrochloride
Lower Extremity Surgery
SKY0402
Hemorrhoid
Bupivacaine liposome
Dental Pain
EXPAREL 266 mg
Posterolateral Thoracotomy
Bupivacaine HCl
Postoperative Pain
FX006 32 mg
Osteoarthritis of the Shoulder
FX005
Osteoarthritis, Knee
TAcs 40 mg
Bilateral Knee Osteoarthritis
Enekinragene Inzadenovec (PCRX-201)
Osteoarthritis (OA) of the Knee
SKY0402 + bupivacaine HCl
Postoperative Pain
TCA IR 40 mg
Osteoarthritis of the Knee
FX006 16 mg
Osteoarthritis of the Knee
FX006 10 mg
Osteoarthritis of the Knee
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TCA IR 40 | Phase 3 | Osteoarthritis of the Knee | - | - |
FX006 | Phase 3 | Osteoarthritis of the Knee | - | - |
EXPAREL 67 mg | Phase 3 | Postoperative Pain | - | - |
ZILRETTA | Phase 3 | Glenohumeral Osteoarthritis | - | - |
Exparel | Phase 3 | Postoperative Pain Management | - | - |
Bupivacaine liposome injectable suspension 266 mg | Phase 3 | Bunionectomy | - | - |
bupivacaine liposome injectable suspension | Phase 3 | Pain | - | - |
Bupivacaine Hydrochloride | Phase 3 | Lower Extremity Surgery | - | - |
SKY0402 | Phase 3 | Hemorrhoid | - | - |
Bupivacaine liposome | Phase 3 | Dental Pain | - | - |
EXPAREL 266 mg | Phase 3 | Posterolateral Thoracotomy | - | - |
Bupivacaine HCl | Phase 3 | Postoperative Pain | - | - |
FX006 32 mg | Phase 3 | Osteoarthritis of the Shoulder | - | - |
FX005 | Phase 2 | Osteoarthritis, Knee | - | - |
TAcs 40 mg | Phase 2 | Bilateral Knee Osteoarthritis | - | - |
Enekinragene Inzadenovec (PCRX-201) | Phase 2 | Osteoarthritis (OA) of the Knee | - | - |
SKY0402 + bupivacaine HCl | Phase 2 | Postoperative Pain | - | - |
TCA IR 40 mg | Phase 2 | Osteoarthritis of the Knee | - | - |
FX006 16 mg | Phase 2 | Osteoarthritis of the Knee | - | - |
FX006 10 mg | Phase 2 | Osteoarthritis of the Knee | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pacira BioSciences, Inc.'s drug pipeline?→
CatalystAlert tracks 20 drug candidates in Pacira BioSciences, Inc.'s (PCRX) pipeline across Phase 3, Phase 2. Its lead program is TCA IR 40 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pacira BioSciences, Inc.'s next FDA catalyst?→
Pacira BioSciences, Inc.'s (PCRX) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PCRX biotech catalysts?→
Add PCRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pacira BioSciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.